Chesney, J. A., In, G. K., Shoushtari, A. N., Moyers, J. T., Samhouri, Y., Johnson, T. T., Amaria, R. N., Ramsingh, G., Renard, C., Duan, R., McLaughlin, L., Warner, A. B. (2025). OBX-115 engineered tumor-infiltrating lymphocyte (TIL) cell therapy with regulatable membrane-bound IL15 (mbIL15) in patients (pts) with immune checkpoint inhibitor (ICI)–resistant advanced melanoma: Phase 1 results of the Agni-01 multicenter study.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.9517